Krsnaa Diagnostics Limited — Investor Meet, 11-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Krsnaa Diagnostics reported Q3 FY26 revenue of 181.2 Cr (up 4% YoY), EBITDA of 47.4 Cr (26% margin), and PAT of 16.8 Cr (9% margin). Q3 was soft due to seasonality and strategic pauses for receivables, recovering 130 Cr. Initial costs for the Rajasthan pathology rollout impacted margins, but management sees it as temporary, projecting 200 Cr annualized revenue from FY27. Retail segment surged 8x YoY. They also launched Apulki, India's first PPP cancer/cardiac hospital. Outlook is confident, emphasizing disciplined growth, efficiency, and capital allocation, with pathology expected to contribute 65-70% of future revenue.